IMM2510 and IMM01 Combination for Advanced Solid Tumors
IMM2510
+ IMM01
Treatment Study
Summary
Study start date: October 15, 2025
Actual date on which the first participant was enrolled.This clinical trial is focused on testing a new combination of drugs for patients with advanced solid tumors, which are types of cancer that have spread beyond their original site. The study aims to see how safe and tolerable two drugs, IMM2510 and IMM01, are when used together, as well as how they move through and affect the body. IMM2510 is a protein that targets proteins involved in cancer growth, while IMM01 is designed to help the immune system fight cancer cells. This research is especially important for patients who have already tried other treatments, as it explores a potential new option for managing their cancer. Participants in the study will receive the medications through injections. The study will gradually increase the dosage to find the most effective and safe amount for patients. Researchers will closely monitor participants to assess any side effects and gather information on how the drugs interact with the body and fight the tumor. The primary goal is to evaluate how well the treatment works against the cancer and to understand any potential risks involved. This study provides an opportunity to advance treatment options for individuals with challenging cancer types.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.104 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age greater than or equal to 18 years old at the same time of signing the informed consent. * Histologically or cytologically confirmed for Solid Tumor. * Eastern Cooperative Oncology Group (ECOG) 0 to 1. * Adequate organ function as defined in protocol. Exclusion Criteria: * History of other malignancy within the past 5 years with exceptions. * Systemic chemotherapy was administered within 3 weeks prior to the first administration. * Activated symptomatic brain metastases and leptomeningeal disease. * History of inflammatory bowel disease. * Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Shanghai Gobroad Cancer Hospital China Pharmaceutical University
Shanghai, ChinaOpen Shanghai Gobroad Cancer Hospital China Pharmaceutical University in Google Maps